Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms?

Robert Sack, Rod J. Hughes, Dale M. Edgar, Alfred Lewy

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Differing conclusions regarding the sleep-promoting effects of melatonin may be the result of the broad range of doses employed (0.1-2000 mg), the differing categories of subjects tested (normal subjects, insomniac patients, elderly, etc.), and the varying times of administration (for daytime vs. nighttime sleep). We conclude that melatonin may benefit sleep by correcting circadian phase abnormalities and/or by a modest direct soporific effect that is most evident following daytime administration to younger subjects. We speculate that these effects are mediated by interactions with specific receptors concentrated in the suprachiasmatic nucleus (SCN) that result in resetting of the circadian pacemaker and/or attenuation of an SCN-dependent circadian alerting process.

Original languageEnglish (US)
Pages (from-to)908-915
Number of pages8
JournalSleep
Volume20
Issue number10
StatePublished - 1997

Fingerprint

Melatonin
Sleep
Suprachiasmatic Nucleus

Keywords

  • Circadian rhythms
  • Insomnia
  • Melatonin
  • Sleep disorders
  • Suprachiasmatic nucleus

ASJC Scopus subject areas

  • Physiology

Cite this

Sack, R., Hughes, R. J., Edgar, D. M., & Lewy, A. (1997). Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms? Sleep, 20(10), 908-915.

Sleep-promoting effects of melatonin : At what dose, in whom, under what conditions, and by what mechanisms? / Sack, Robert; Hughes, Rod J.; Edgar, Dale M.; Lewy, Alfred.

In: Sleep, Vol. 20, No. 10, 1997, p. 908-915.

Research output: Contribution to journalArticle

Sack, R, Hughes, RJ, Edgar, DM & Lewy, A 1997, 'Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms?', Sleep, vol. 20, no. 10, pp. 908-915.
Sack, Robert ; Hughes, Rod J. ; Edgar, Dale M. ; Lewy, Alfred. / Sleep-promoting effects of melatonin : At what dose, in whom, under what conditions, and by what mechanisms?. In: Sleep. 1997 ; Vol. 20, No. 10. pp. 908-915.
@article{909504298b92486e9cf8199bf8dea820,
title = "Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms?",
abstract = "Differing conclusions regarding the sleep-promoting effects of melatonin may be the result of the broad range of doses employed (0.1-2000 mg), the differing categories of subjects tested (normal subjects, insomniac patients, elderly, etc.), and the varying times of administration (for daytime vs. nighttime sleep). We conclude that melatonin may benefit sleep by correcting circadian phase abnormalities and/or by a modest direct soporific effect that is most evident following daytime administration to younger subjects. We speculate that these effects are mediated by interactions with specific receptors concentrated in the suprachiasmatic nucleus (SCN) that result in resetting of the circadian pacemaker and/or attenuation of an SCN-dependent circadian alerting process.",
keywords = "Circadian rhythms, Insomnia, Melatonin, Sleep disorders, Suprachiasmatic nucleus",
author = "Robert Sack and Hughes, {Rod J.} and Edgar, {Dale M.} and Alfred Lewy",
year = "1997",
language = "English (US)",
volume = "20",
pages = "908--915",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "10",

}

TY - JOUR

T1 - Sleep-promoting effects of melatonin

T2 - At what dose, in whom, under what conditions, and by what mechanisms?

AU - Sack, Robert

AU - Hughes, Rod J.

AU - Edgar, Dale M.

AU - Lewy, Alfred

PY - 1997

Y1 - 1997

N2 - Differing conclusions regarding the sleep-promoting effects of melatonin may be the result of the broad range of doses employed (0.1-2000 mg), the differing categories of subjects tested (normal subjects, insomniac patients, elderly, etc.), and the varying times of administration (for daytime vs. nighttime sleep). We conclude that melatonin may benefit sleep by correcting circadian phase abnormalities and/or by a modest direct soporific effect that is most evident following daytime administration to younger subjects. We speculate that these effects are mediated by interactions with specific receptors concentrated in the suprachiasmatic nucleus (SCN) that result in resetting of the circadian pacemaker and/or attenuation of an SCN-dependent circadian alerting process.

AB - Differing conclusions regarding the sleep-promoting effects of melatonin may be the result of the broad range of doses employed (0.1-2000 mg), the differing categories of subjects tested (normal subjects, insomniac patients, elderly, etc.), and the varying times of administration (for daytime vs. nighttime sleep). We conclude that melatonin may benefit sleep by correcting circadian phase abnormalities and/or by a modest direct soporific effect that is most evident following daytime administration to younger subjects. We speculate that these effects are mediated by interactions with specific receptors concentrated in the suprachiasmatic nucleus (SCN) that result in resetting of the circadian pacemaker and/or attenuation of an SCN-dependent circadian alerting process.

KW - Circadian rhythms

KW - Insomnia

KW - Melatonin

KW - Sleep disorders

KW - Suprachiasmatic nucleus

UR - http://www.scopus.com/inward/record.url?scp=0030778136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030778136&partnerID=8YFLogxK

M3 - Article

C2 - 9415954

AN - SCOPUS:0030778136

VL - 20

SP - 908

EP - 915

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 10

ER -